We have recently reported that the analgesics morphine and buprenorphine and the neuroleptic haloperidol exert some of their effects via dopaminergic systems in the rat brain (Cowan et al., 197Sa,b). Thus morphine and buprenorphine in rats previously unilaterally lesioned with 6-hydroxydopamine (2,4,5-trihydroxyphenethylamine) in the nigrostriatal pathway both initiate circling in the same direction as (+)-amphetamine, whereas morphine, buprenorphine and haloperidol all inhibit apomorphine induced circling. The circling behaviour initiated by the analgesics and (+)-amphetamine was antagonized by the narcotic antagonist naloxone (P. W. Dettmar, A. Cowan & D. S.
We have recently reported that the analgesics morphine and buprenorphine and the neuroleptic haloperidol exert some of their effects via dopaminergic systems in the rat brain (Cowan et al., 197Sa, b) . Thus morphine and buprenorphine in rats previously unilaterally lesioned with 6-hydroxydopamine (2,4,5-trihydroxyphenethylamine) in the nigrostriatal pathway both initiate circling in the same direction as (+)-amphetamine, whereas morphine, buprenorphine and haloperidol all inhibit apomorphine induced circling. The circling behaviour initiated by the analgesics and (+)-amphetamine was antagonized by the narcotic antagonist naloxone (P. W. Dettmar, A. Cowan & D. S.
Walter, unpublished observations), as 'was the inhibition of apomorphine-induced circling by the two analgesics, but not that of the neuroleptic haloperidol.
In an attempt to correlate these data with biochemical activity, these agents have been studied for their effects in the rat brain on the turnover rate of noradrenaline and dopamine (3,4-dihydroxyphenethylamine) and on the concentration of their major metabolites 3-methoxy-4-hydroxyphenylglycol and homovanillic acid.
The turnover rates were measured by following the decrease in noradrenaline and dopamine concentrations after the intraperitoneal administration of 320mg of a-methyl-p-tyrosine methyl ester hydrochloride/kg (Brodie et a[., 1966) . The concentrations of noradrenaline and dopamine were measured after their 0-methylation to normetanephrine and 3-methoxytyramine in the presence of S-adenosyl-~-[methyl-~H]methionine (Cuello et al., 1973) . 3-Methoxy-Chydroxyphenylglycol was measured by the method of Walter 8~ Shilcock (1977) and homovanillic acid by the method of Walter et al. (1978) .
Buprenorphine (O.l-lOmg/kg), morphine (3-30mg/kg) and haloperidol (0.03-1 mg/ kg) dosed subcutaneously, all caused increases in the rate of turnover of dopamine, whereas only morphine at 30mg/kg increased the noradrenaline turnover rate. At these doses, no changes in the steady-state concentrations of either noradrenaline or dopamine occurred.
(+)-Amphetamine dosed subcutaneously, however, significantly decreased both noradrenaline and dopamine steady-state brain concentrations, which was reflected in the apparent increase in turnover rates of these amines. It was interesting that a marked decrease in noradrenaline occurred at both lOmg/kg (25% P<0.05) and 30mg/kg (67% P<O.oOl), whereas 30mg/kg (28% P<O.OOl) had to be given to cause a decrease in the dopamine concentration.
We have reported elsewhere (Cowan et a[., 1976) that buprenorphine at some but not all doses and haloperidol cause increases in rat brain homovanillic acid concen- Table 1 . Effects of naloxone on changes in rates of catecholamine furnooer caused by buprenorphine, morphine, haloperidol and (+)-amphetamine Naloxone (3-30mg/kg) or 0.9% NaCl was injected subcutaneously in the flank 5min before the sequential intraperitoneal dosing of a-methyl-ptyrosine methyl ester hydrochloride (320mg/kg) and then the test drug was injected subcutaneously in the neck. The effect on the forebrain noradrenaline and dopamine concentrations of Sprague-Dawley rats (160-180g, five animals) at 2 h after dosing is shown. Mean turnover rates were calculated as in Brodie et al. (1966) . In the absence of the test drug, naloxone (3-30mg/kg) did not alter noradrenaline or dopamine turnover rates.
Statistical comparisons were made with Student's t-test for unpaired data: *0.9 % NaCl/test drug versus 0.9 % NaC1/0.9 % NaCl or 0.9 % NaCl citric acid; tnaloxone/test drug versus 0.9 % NaCl/test drug. Abbreviation: NS, not significant. All drugs were dissolved in 0.9 % NaCl except halo- 
<0.02t
----trations, whereas morphine up to 30mg/kg had no effect. Although (+)-amphetamine (30mg/kg) depletes brain dopamine, no increase of homovanillic acid occurred with the doses of 3-30mg/kg. Similarly, the noradrenaline-depleting effect of (+)-amphetamine was not reflected in the brain 3-methoxy-4-hydroxyphenylglycol concentration, since only a very small increase occurred at lOmg/kg (+)-amphetamine and no increase at 30mg/kg. The narcotic antagonist naloxone has been used to indicate that pharmacological actions of analgesics are occurring via opiate receptors. The effects of morphine and buprenorphine on dopamine turnover rates were reversed by naloxone at 3-30mg/kg dosed subcutaneously 5 min before the analgesics, whereas no such antagonism of the increased rate of dopamine turnover caused by haloperidol was observed (Table 1) .
These data compare well with earlier observations that the buprenorphine-induced rise, but not the haloperidol-induced rise of homovanillic acid was antagonized by naloxone (Cowan et al., 1976) . It was interesting, however, that naloxone dosed subcutaneously at 3mg/kg 5min before 30mg of (+)-amphetamine/kg also antagonized the increase in the rate of turnover of dopamine, whereas in the same rats it had no effect on the increased noradrenaline turnover rate (Table 1) .
It is unlikely that (+)-amphetamine and naloxone are competing for the same receptor, but rather that naloxone is affecting the activity of an endogenous opiate system which is modulating dopaminergic activity. The fact that naloxone reverses the increased dopamine, but not the increased noradrenaline, turnover rate after (+)-amphetamine administration points to clear differences in the control of the two systems.
Naloxone was generously supplied by Endo Laboratories, Garden City, NY, U S A Ther. 154, [493] [494] [495] [496] [497] [498] 
